Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idefirix in imlifidase-desensitised kidney transplant patients with positive crossmatch
2024-511810-18-00Phase 3Completed
- Sponsor
- Hansa Biopharma
- Start
- Sep 2024
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 11
01
Overview
Phase 3, open-label trial of efgartigimod alfa in chronic kidney disease (CKD), end-stage kidney disease (ESKD) and kidney allograft rejection (3 cohorts), sponsored by Hansa Biopharma. Primary endpoint: 1-year graft failure-free survival in imlifidase-treated transplanted patients. Started Sep 2024; status: completed.
02
Drugs
efgartigimod alfa
03
Conditions
chronic kidney disease (CKD)end-stage kidney disease (ESKD)kidney allograft rejection
Beyond the preview
Go deeper on 2024-511810-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511810-18-00.